http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 19 Feb 2026 08:00:00 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 +0000 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 +0000 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 +0000 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 +0000 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 +0000 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 +0000 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Press+Releases/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 +0000 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 +0000 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 +0000 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 +0000 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 +0000 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 +0000 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 +0000 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html <ul class="bwlistdisc"> <li> <b>New chemistry reduces barriers to scaling single-cell studies across research settings</b> </li> <li> <b>Launch planned for March 2026, available across Evercode Whole Transcriptome product line</b> </li> </ul> <p> SEATTLE, Wash. &amp; VENLO, the Netherlands--(BUSINESS WIRE)-- Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. </p><p> Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers to http://www.streetinsider.com/Business+Wire/Parse+Biosciences+Launches+Evercode+Whole+Transcriptome+V4+With+Shorter+Workflow%2C+Higher+Sensitivity+and+Higher+Cell+Recovery/26026266.html Thu, 19 Feb 2026 08:00:00 +0000 A.09642568 A.50210275 O.00543542 O.20371933 O.31525930 QGEN QIA http://www.streetinsider.com/Investing/Qiagen+guides+to+at+least+5%25+sales+growth+in+2026/25947823.html (Updated - February 4, 2026 4:40 PM EST) <p>Investing.com -- Qiagen NV (NYSE:QGEN) reported fourth-quarter adjusted per share profit of 62 cents and sales of $540 million, thanks to growth in tuberculosis testing and diagnostics. Shares were down 3% in New York. </p><p>The diagnostics group said adjusted profit rose 6% to $522 million, for 2025, while adjusted EPS increased 10% at constant exchange rates to $2.40, beating its prior forecast of about $2.38.<br /><br />Revenue climbed 6% to $2.09 billion, or 5% at constant exchange rates, the top end of its guidance range.</p><p>Growth for the year was driven by strong demand http://www.streetinsider.com/Investing/Qiagen+guides+to+at+least+5%25+sales+growth+in+2026/25947823.html Wed, 04 Feb 2026 16:40:08 +0000 QGEN QIA http://www.streetinsider.com/Investing/Qiagen+guides+to+at+least+5%25+sales+growth+in+2026/25947823.html (Updated - February 4, 2026 4:40 PM EST) <p>Investing.com -- Qiagen NV (NYSE:QGEN) reported fourth-quarter adjusted per share profit of 62 cents and sales of $540 million, thanks to growth in tuberculosis testing and diagnostics. Shares were down 3% in New York. </p><p>The diagnostics group said adjusted profit rose 6% to $522 million, for 2025, while adjusted EPS increased 10% at constant exchange rates to $2.40, beating its prior forecast of about $2.38.<br /><br />Revenue climbed 6% to $2.09 billion, or 5% at constant exchange rates, the top end of its guidance range.</p><p>Growth for the year was driven by strong demand http://www.streetinsider.com/Investing/Qiagen+guides+to+at+least+5%25+sales+growth+in+2026/25947823.html Wed, 04 Feb 2026 16:40:08 +0000 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html <ul class="bwlistdisc"> <li> <b>Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.62</b> <ul class="bwlistcircle"> <li> <b>Net sales growth of 1% CER ahead of outlook for steady results vs. Q4 2024, adjusted diluted EPS of $0.62 CER ahead of outlook of about $0.60 CER</b> </li> </ul> </li> <li> <b>FY 2025: Net sales of $2.09 billion (+6% at actual rates, +5% CER) at high end of outlook for 4-5% CER growth, adj. diluted EPS of $2.40 CER ahead of outlook of about $2.38 CER</b> <ul class="bwlistcircle"> <li> <b>Growth pillars on target and deliver $1.49 billion CER of http://www.streetinsider.com/Press+Releases/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html Wed, 04 Feb 2026 16:05:00 +0000 A.09642568 O.00543542 O.20371933 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html <ul class="bwlistdisc"> <li> <b>Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.62</b> <ul class="bwlistcircle"> <li> <b>Net sales growth of 1% CER ahead of outlook for steady results vs. Q4 2024, adjusted diluted EPS of $0.62 CER ahead of outlook of about $0.60 CER</b> </li> </ul> </li> <li> <b>FY 2025: Net sales of $2.09 billion (+6% at actual rates, +5% CER) at high end of outlook for 4-5% CER growth, adj. diluted EPS of $2.40 CER ahead of outlook of about $2.38 CER</b> <ul class="bwlistcircle"> <li> <b>Growth pillars on target and deliver $1.49 billion CER of http://www.streetinsider.com/Press+Releases/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html Wed, 04 Feb 2026 16:05:00 +0000 A.09642568 O.00543542 O.20371933 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html <ul class="bwlistdisc"> <li> <b>Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.62</b> <ul class="bwlistcircle"> <li> <b>Net sales growth of 1% CER ahead of outlook for steady results vs. Q4 2024, adjusted diluted EPS of $0.62 CER ahead of outlook of about $0.60 CER</b> </li> </ul> </li> <li> <b>FY 2025: Net sales of $2.09 billion (+6% at actual rates, +5% CER) at high end of outlook for 4-5% CER growth, adj. diluted EPS of $2.40 CER ahead of outlook of about $2.38 CER</b> <ul class="bwlistcircle"> <li> <b>Growth pillars on target and deliver $1.49 billion CER of http://www.streetinsider.com/Press+Releases/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html Wed, 04 Feb 2026 16:05:00 +0000 A.09642568 O.00543542 O.20371933 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html <ul class="bwlistdisc"> <li> <b>Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.62</b> <ul class="bwlistcircle"> <li> <b>Net sales growth of 1% CER ahead of outlook for steady results vs. Q4 2024, adjusted diluted EPS of $0.62 CER ahead of outlook of about $0.60 CER</b> </li> </ul> </li> <li> <b>FY 2025: Net sales of $2.09 billion (+6% at actual rates, +5% CER) at high end of outlook for 4-5% CER growth, adj. diluted EPS of $2.40 CER ahead of outlook of about $2.38 CER</b> <ul class="bwlistcircle"> <li> <b>Growth pillars on target and deliver $1.49 billion CER of http://www.streetinsider.com/Press+Releases/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html Wed, 04 Feb 2026 16:05:00 +0000 A.09642568 O.00543542 O.20371933 QGEN QIA http://www.streetinsider.com/Press+Releases/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html <ul class="bwlistdisc"> <li> <b>Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.62</b> <ul class="bwlistcircle"> <li> <b>Net sales growth of 1% CER ahead of outlook for steady results vs. Q4 2024, adjusted diluted EPS of $0.62 CER ahead of outlook of about $0.60 CER</b> </li> </ul> </li> <li> <b>FY 2025: Net sales of $2.09 billion (+6% at actual rates, +5% CER) at high end of outlook for 4-5% CER growth, adj. diluted EPS of $2.40 CER ahead of outlook of about $2.38 CER</b> <ul class="bwlistcircle"> <li> <b>Growth pillars on target and deliver $1.49 billion CER of http://www.streetinsider.com/Press+Releases/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html Wed, 04 Feb 2026 16:05:00 +0000 A.09642568 O.00543542 O.20371933 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html <ul class="bwlistdisc"> <li> <b>Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.62</b> <ul class="bwlistcircle"> <li> <b>Net sales growth of 1% CER ahead of outlook for steady results vs. Q4 2024, adjusted diluted EPS of $0.62 CER ahead of outlook of about $0.60 CER</b> </li> </ul> </li> <li> <b>FY 2025: Net sales of $2.09 billion (+6% at actual rates, +5% CER) at high end of outlook for 4-5% CER growth, adj. diluted EPS of $2.40 CER ahead of outlook of about $2.38 CER</b> <ul class="bwlistcircle"> <li> <b>Growth pillars on target and deliver $1.49 billion CER of http://www.streetinsider.com/Business+Wire/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html Wed, 04 Feb 2026 16:05:00 +0000 A.09642568 O.00543542 O.20371933 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html <ul class="bwlistdisc"> <li> <b>Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.62</b> <ul class="bwlistcircle"> <li> <b>Net sales growth of 1% CER ahead of outlook for steady results vs. Q4 2024, adjusted diluted EPS of $0.62 CER ahead of outlook of about $0.60 CER</b> </li> </ul> </li> <li> <b>FY 2025: Net sales of $2.09 billion (+6% at actual rates, +5% CER) at high end of outlook for 4-5% CER growth, adj. diluted EPS of $2.40 CER ahead of outlook of about $2.38 CER</b> <ul class="bwlistcircle"> <li> <b>Growth pillars on target and deliver $1.49 billion CER of http://www.streetinsider.com/Business+Wire/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html Wed, 04 Feb 2026 16:05:00 +0000 A.09642568 O.00543542 O.20371933 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html <ul class="bwlistdisc"> <li> <b>Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.62</b> <ul class="bwlistcircle"> <li> <b>Net sales growth of 1% CER ahead of outlook for steady results vs. Q4 2024, adjusted diluted EPS of $0.62 CER ahead of outlook of about $0.60 CER</b> </li> </ul> </li> <li> <b>FY 2025: Net sales of $2.09 billion (+6% at actual rates, +5% CER) at high end of outlook for 4-5% CER growth, adj. diluted EPS of $2.40 CER ahead of outlook of about $2.38 CER</b> <ul class="bwlistcircle"> <li> <b>Growth pillars on target and deliver $1.49 billion CER of http://www.streetinsider.com/Business+Wire/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html Wed, 04 Feb 2026 16:05:00 +0000 A.09642568 O.00543542 O.20371933 QGEN QIA http://www.streetinsider.com/Business+Wire/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html <ul class="bwlistdisc"> <li> <b>Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.62</b> <ul class="bwlistcircle"> <li> <b>Net sales growth of 1% CER ahead of outlook for steady results vs. Q4 2024, adjusted diluted EPS of $0.62 CER ahead of outlook of about $0.60 CER</b> </li> </ul> </li> <li> <b>FY 2025: Net sales of $2.09 billion (+6% at actual rates, +5% CER) at high end of outlook for 4-5% CER growth, adj. diluted EPS of $2.40 CER ahead of outlook of about $2.38 CER</b> <ul class="bwlistcircle"> <li> <b>Growth pillars on target and deliver $1.49 billion CER of http://www.streetinsider.com/Business+Wire/QIAGEN+Exceeds+Q4+2025+Outlook+Driven+by+Growth+Pillars/25946782.html Wed, 04 Feb 2026 16:05:00 +0000 A.09642568 O.00543542 O.20371933 QGEN QIA